Navigation Links
Prism Pharmaceuticals' Study of Injectable Clopidogrel Accepted for Presentation at the American College of Cardiology
Date:2/9/2009

- First time IV formulation of clopidogrel, the active ingredient in

PLAVIX(R), is studied in humans -

KING OF PRUSSIA, Pa., Feb. 9 /PRNewswire/ -- Prism Pharmaceuticals announced today that the results of the first-in-man study of PM103, a novel intravenous formulation of clopidogrel bisulfate (the active ingredient in PLAVIX(R)), has been accepted for poster presentation at the 58th Scientific Session of the American College of Cardiology (ACC) on March 29-31, 2009. The poster will be presented at the ACC's Innovation in Intervention: i2 Summit 2009 in partnership with Cardiovascular Research Foundation.

    Presentation Number: 2515-749

    Abstract Title:     Assessment of the pharmacokinetic and pharmacodynamic
                        effects of intravenous clopidogrel in humans

    Time:               Monday, Mar 30, 2009, 9:30 AM -10:30 AM

    Topic:              Pharmacotherapy - Interventional Aspects

    Authors:            Daniel Cushing, Raymond Lipicky, Peter Kowey,
                        Christopher Cannon, Michael Adams, Warren Cooper,
                        Gerold Mosher, Prism Pharmaceuticals

"We are very pleased to present the first data in humans of an IV formulation of clopidogrel at this most prestigious cardiology scientific session," said Dr. Warren D. Cooper, President and CEO of Prism. "PM103 is Prism's second acute care cardiovascular product that is being developed through our accelerated model, which focuses on bringing novel and improved formulations of existing compounds to the market."

About PM103

PM103 is a proprietary, novel intravenous formulation of clopidogrel bisulfate. Clopidogrel is the active ingredient in PLAVIX(R) (clopidogrel bisulfate), an orally available antiplatelet drug marketed by Bristol-Myers Squibb and sanofi-aventis. PM103 is being developed in collaboration with CyD
'/>"/>

SOURCE Prism Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Prism Pharmaceuticals Appoints Maurits Geerlings Vice President of Business Development
2. New Empire BlueCross BlueShield Prism Plans Offer Better Choice and Affordability for New York Small Group Market
3. Prism glasses expand the view for patients with hemianopia
4. Prism Pharmaceuticals Receives FDA Approval of NEXTERONE(R) for Life-Threatening Ventricular Fibrillation and Ventricular Tachycardia
5. Prism Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference
6. Prism Pharmaceuticals to Receive $10 Million Milestone Payment from Paul Capital Healthcare
7. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
8. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
9. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... New York (PRWEB) December 25, 2014 ... 2010 DePuy ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) continue ... reports. According to an Order issued in the U.S. ... the Court will convene an open conference on January ... and United States Courthouse in West Palm Beach, Florida. ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 The short film ... was created in honor of a true 9/11 hero, Welles ... film festivals including the 24 hours of Nuremberg International Short ... Bangladesh. , Actress, screenwriter and director Luciana Lagana ... this film together with her husband, Gregory Graham ...
(Date:12/25/2014)... When head lice hits a home or school, parents ... rid of it while keeping it from taking over the ... the solution right in their neighborhood: Lice Troopers . ... full spectrum head lice screening and treatment services to families ... Biscayne, Brickell, Coconut Grove, Kendall, Pinecrest and South Miami. , ...
(Date:12/25/2014)... is common during the holidays, but there are strategies that ... "Don,t arrive at a party hungry. It may seem logical ... a party, but deprivation leads to hunger, and hunger leads ... in Mount Kisco, N.Y., said in a hospital news release. ... even to have a snack before attending a party when ...
(Date:12/25/2014)... December 25, 2014 Thousands of transvaginal ... forward in a number of multidistrict litigations currently underway ... Bernstein Liebhard LLP reports. According to an Order issued ... convene a Joint Status Conference in all of the ... have been directed to submit a proposed agenda to ...
Breaking Medicine News(10 mins):Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4
... Gadolinium based contrast agents, frequently used during computed tomography (CT) ... associated with a very low rate of adverse effects, according ... of the American Journal of Roentgenology ( AJR ... Rochester, MN, included a total of 456,930 contrast doses administered. ...
... NASHVILLE, Tenn., Sept. 21 The bump on his ... out of surgical specialty training, craniofacial and maxillofacial surgeon Dr. Stephen ... hospital. Then came the biopsy results: the little nuisance was in ... After the first round of surgical procedures, Cantrell enrolled in a ...
... , Second Annual Event Promotes ... WASHINGTON, Sept. 20 Secretary of Veterans Affairs Eric K. Shinseki offered ... of the 2nd National Veterans Summer Sports Clinic in San Diego. ... Shinseki kicked-off the clinic by telling his personal story of dealing with ...
... let their legs move, bear weight without brain signals ... approach to treating spinal cord injuries allowed paralyzed rats ... report. , Spinal cord injuries result in paralysis when ... the brain are damaged or severed. Much of the ...
... NEW ORLEANS, Sept. 20 Jack Mackenroth, from the hit ... 20th annual NO/AIDS Walk and is bringing Living Positive By ... city. On Sunday, September 20th, Jack will participate in the Walk ... several other AIDS Service Organizations in Louisiana each year. The ...
... ... treatment program in the U.S., reNEW MAN (renewman.com) is promoting its national network of ... and older, the company helps connect professional men that exhibit signs of low testosterone ... safe-individualized treatments. , ...
Cached Medicine News:Health News:Surgeon Battling Own Cancer Developed New Treatment 2Health News:Surgeon Battling Own Cancer Developed New Treatment 3Health News:Secretary Shinseki Kicks-Off National Sports Clinic 2Health News:Paralyzed Rats Walk Again 2Health News:Paralyzed Rats Walk Again 3Health News:REPEAT: 'Project Runway' Designer in New Orleans to Educate About Living with HIV and Combat Stigma Associated with the Disease through Living Positive By Design 2Health News:REPEAT: 'Project Runway' Designer in New Orleans to Educate About Living with HIV and Combat Stigma Associated with the Disease through Living Positive By Design 3Health News:Find a Local Andropause Doctor to Treat Low Testosterone with reNEW MAN 2Health News:Find a Local Andropause Doctor to Treat Low Testosterone with reNEW MAN 3Health News:Find a Local Andropause Doctor to Treat Low Testosterone with reNEW MAN 4
(Date:12/24/2014)... 2014 Echo Therapeutics, Inc. (NASDAQ: ... on skin permeation, continuous glucose monitoring and associated ... has been appointed Chief Executive Officer effective ... 20 years of experience in the medical device, ... served as Vice President, Business Development, Otsuka Pharmaceuticals as ...
(Date:12/24/2014)... 23, 2014   Synageva BioPharma Corp. ... developing therapeutic products for rare disorders, today announced ... the Marketing Authorization Application (MAA) for sebelipase alfa ... company,s request for accelerated assessment, which has the ... The MAA, and the Biologics ...
(Date:12/24/2014)... Tianyin Pharmaceutical Co., Inc. (NYSE MKT: ... biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics ... the Company achieved the Public Notice (Gong Shi) ... of TPI,s Qionglai Facility (QLF) from the China ... period is a significant procedure of GMP certification ...
Breaking Medicine Technology:Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3
... Newly-Identified K-Ras Mutated Oncogene Population in Patients with ... in Advanced Breast and ... Ovarian Cancers, ... ) today announced an expanded Phase 2 development,plan for NKTR-102 (PEG-irinotecan). ...
... Annual Meeting - - Conference call to be hosted Wednesday, June ... ... BRANFORD, Conn., June 1 CuraGen Corporation,(Nasdaq: CRGN ) today presented ... of unresectable Stage III or,Stage IV melanoma. The results were presented by ...
Cached Medicine Technology:Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan) 2Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan) 3Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan) 4Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan) 5CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma 2CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma 3CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma 4CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma 5CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma 6
... The Alaris System integrates drug ... practice guidelines,into a single, modular platform. ... or remove modules as you,need them, ... the bedside,to a minimum while managing ...
... Eraser instruments have been designed to ... right tool for situations requiring precise ... of 25 gauge intraocular, bipolar, diathermy ... of target tissues for fine-tip hemostasis ...
... steps any hospital or health system can ... most effective tools available for physicians and ... documentation and electronic medical record (EMR) system, ... goal. In fact, its the most reliable ...
... These specialty Eraser instruments have ... surgeon with the right tool for ... introduced a series of 25 gauge ... provide discrete treatment of target tissues ...
Medicine Products: